A discovery in the UCD Hammock Lab may lead to treatment of Alzheimer’s

A discovery in the UCD Hammock Lab may lead to treatment of Alzheimer’s

Inhibitors of a key regulatory enzyme in humans and experimental animals studied in the lab of UC Davis distinguished professor Bruce Hammock may lead to a role in treating people with Alzheimer’s disease by reducing inflammation in the brain.

“Inflammation in the brain, or neuorinflammation, is strongly implicated in Alzheimer’s disease,” said Hammock, co-author of a research paper, “An Epoxide Hydrolase Inhibitor Reduces Neuroinflammation in a Mouse Model of Alzheimer’s Disease,” published Dec. 9 in the journal Science Translational Medicine. Bruce Hammock “This paper is getting worldwide attention, and I hope it stimulates research on the role of lipid mediators in brain health” said Hammock, who holds a joint appointment with the department of entomology and nematology and the UC Davis Comprehensive Cancer Center.

Some 5.8 million Americans have Alzheimer’s disease, an irreversible brain disease that slowly destroys memory and thinking skills.

A team of eight scientists, led by Hui Zheng of the Baylor College of Medicine, Houston, explained that the enzyme, soluble epoxide hydrolase (sEH), is elevated in the brains of patients with Alzheimer’s disease and in an amyloid mouse model with AD. Blocking sEH “may replenish the natural epoxy lipids, combat neuroinflammation, and improve cognition,” they said.

Hammock describes sEH as a key regulatory enzyme involved in the metabolism of fatty acids. It regulates a new class of natural chemical mediators, which in turn resolve inflammation while reducing blood pressure and pain. Hammock and his lab have been involved in research on this enzyme for more than 50 years.

“Inflammatory processes are known to be associated with the pathology and neurodegeneration associated with Alzheimer’s disease,” said Dr. Charles DeCarli, director of UC Davis Health’s Alzheimer’s Disease Center, a National Institutes of Health-funded research center funded by the National Institutes of Health. “While the exact mechanisms remain elusive, these new data offer a unique avenue for novel therapeutic development and may be the first step in the process of finding an effective treatment for Alzheimer’s disease.”

DeCarli, who was not involved in the Baylor-UC Davis study, is a distinguished professor of neurology in the Department of Neurology and the Center for Neuroscience. He serves as the Victor and Genevieve Orsi Chair in Alzheimer’s Research and directs the Imaging of Dementia and Aging laboratory.

The team, including three researchers from the Hammock lab — Hammock, Sung Hee Hwang and Debin Wan — and five from Baylor — Zheng, Anamitra Ghosh, Michele Comerota, Fading Chen, Nicholas Propson — identified a lipid metabolic pathway regulating neuroinflammation. Further development of sEH inhibitors may lead to a potential treatment for AD, they said.

In their abstract, the scientists explained that epoxy fatty acids “are derivatives of the arachidonic acid and omega-3 fatty acid metabolism pathways and have anti-inflammatory activities. However, their beneficial efficacy is limited because of their rapid hydrolysis by the soluble epoxide hydrolase (sEH).”

Zheng, director and professor of Baylor’s Huffington Center on Aging, also holds joint appointments with Baylor’s department of molecular and cellular biology and the department of molecular and human genetics. Her laboratory focuses on basic and translational research on Alzheimer’s disease.

“Our expertise is mouse genetics, and we are known for using sophisticated mouse models and innovative approaches to probe the biology and pathophysiology of AD,” she wrote on her website.

Hammock added: “We have been lucky to collaborate with the scientists from Baylor and others around the world to find ways to resolve inflammation and reduce chronic diseases of aging. One of our sEH inhibitors is in human safety trials on a clinical path to treat chronic pain, we are hopeful that the compound also can be repurposed to ameliorate symptoms of diseases in the central nervous system.”

Of the 5.8 million Americans who have Alzheimer’s, around 5.3 million are 65 and older, according to the Alzheimer’s Association. About two-thirds are women. “African-Americans are about twice as likely to have Alzheimer’s disease or other forms of dementia as whites. Hispanics are about 1.5 times as likely to have Alzheimer’s disease or other forms of dementia as whites.”

The National Institute on Aging indicates that the prevalence of Alzheimer’s disease doubles every five years beyond the age of 65. At present, someone in the U.S. develops Alzheimer’s disease every 66 seconds. Worldwide, some 44 million people have Alzheimer’s.

Read more at www.davisenterprise.com

Spread the love

Leave a Reply

Nature Knows Nootropics